Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
出版年份 2023 全文链接
标题
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial
作者
关键词
-
出版物
LANCET
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-11-03
DOI
10.1016/s0140-6736(23)02230-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Fluid retention and heart failure in the PRECISION trial
- (2023) Donald E Kohan et al. LANCET
- The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan
- (2023) Vandana Veenit et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial
- (2023) Hiddo J L Heerspink et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
- (2022) Markus P Schlaich et al. LANCET
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
- (2022) Colin Baigent et al. LANCET
- Empagliflozin in Patients with Chronic Kidney Disease
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
- (2021) Simke W. Waijer et al. Clinical Journal of the American Society of Nephrology
- Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
- (2021) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
- (2021) Niels Jongs et al. Lancet Diabetes & Endocrinology
- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2020) Boris Bikbov et al. LANCET
- Novel strategy to monitor fluid absorption and blood loss during urological endoscopic surgery
- (2020) Yunxin Zhang et al. Translational Andrology and Urology
- Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial
- (2020) Megumi Oshima et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction
- (2020) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
- (2019) Hiddo J L Heerspink et al. LANCET
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
- (2019) Kitty J Jager et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Endothelin and endothelin antagonists in chronic kidney disease
- (2014) Donald E Kohan et al. KIDNEY INTERNATIONAL
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Endothelin antagonists for diabetic and non-diabetic chronic kidney disease
- (2012) Donald E. Kohan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy
- (2011) D. E. Kohan et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Zibotentan for the treatment of castrate-resistant prostate cancer
- (2010) Dale R Shepard et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Avosentan for Overt Diabetic Nephropathy
- (2010) J. F.E. Mann et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search